Addressing the problem of insufficient antibiotic drug supply in the healthcare sector, an infectious disease physician Dr. Cornelius Clancy said that this condition is caused because the development of antimicrobials is economically unattractive for Larger pharmaceutical companies. And while numerous initiatives are taken to bring down resistance, Tedros, who is the director-general of the United Nations’ international public health agency mentioned that countries as a whole and the pharmaceutical industry need to get up and go add to the effort through sustainable funding and by creating new medicines for antibiotic-resistant bacteria

According to Clancy, it is possible to find ways to work inside the boundaries of the free-market system to make new antibiotics. She wants to construct a structure where the return on an antibiotic is not particularly related to the number of prescriptions made concerning it. In the U.S, because of its promise to provide fair reimbursement to hospitals for covering the costs of utilizing new antibiotics, the Disarm Act is gaining support. The UK is looking forward to putting together a subscription system that allows hospitals to purchase licenses for antibiotics instead of paying per unit.

Though new drugs need to be developed for safeguarding people against antibiotic-resistant bacteria, medical officials should also be alert about when and how they regulate antibiotics and make people aware of preventive measures as well. Developing new drugs isn’t the only thing we need to do to protect ourselves against antibiotic-resistant bacteria, the WHO added — health professionals around the world also need to be judicious about when and how they administer antibiotics, as well as helping to prevent infections in the first place. Modern medicine depends on antibiotics as medical practices like transplants and cancer medicaments may make people prone to infection, Clancy said.